Trial Endpoints in Prostate Cancer

In a live event, Vinay Minocha, MD, discusses the addition of darolutamide to androgen deprivation therapy for in patients with metastatic hormone-sensitive prostate cancer.

Adam Weiner, MD, discusses his journey toward becoming an oncologist with a focus in urology in this episode of Emerging Experts.

In an interview, Paolo Ghia, MD, PhD, discussed updated data from the phase 2 CAPTIVATE trial of ibrutinib and venetoclax in chronic lymphocytic leukemia/small lymphocytic lymphoma.

In this episode of Emerging Experts, Nazli Dizman, MD, shares the intricacies of her journey towards becoming an oncologist in the United States.

In an interview, Cedric Pobel, MD, further discussed the PEACE-1 trial and its findings.

In an interview with Peers & Perspectives in Oncology, Michael S. Leapman, MD, MHS, discusses the significance of a 10-year rise in active surveillance and watchful waiting in patients with intermediate-risk prostate cancer.